Article
Tumor Regression and Improved Patient Performance are Among the Early Findings Excerpt from the Press Release: OAKLAND, Calif.–(BUSINESS WIRE)–SonALAsense, a pioneer in the development of non-invasive Sonodynamic Therapy (SDT) using SONALA-001 (aminolevulinic acid HCl) in combination with Insightec’s Exablate 4000 Type-2 ultrasound device today announced the presentation of positive preliminary data from the ongoing Phase…
Read More
Plans to report topline data mid-second quarter 2024 Excerpt from the Press Release: REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its RZ402 Phase 2 study in diabetic macular…
Read More
— Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT — — ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 — — Caribou plans to initiate Phase…
Read More
Excerpt from the Press Release: Although a 1972 United Nations (UN) resolution prohibits member states from using biological weapons on military personnel and civilians (1, 2), a lack of robust verification protocols has enabled several countries to develop such agents (3). Several groups that the UN considers to be global terrorist organizations also are establishing…
Read More
Excerpt from the Press Release: While a recent report issued by the Centers for Disease Control and Prevention (CDC) noted that 30 percent of children with autism were not diagnosed at eight years of age, emerging research suggests that a combination of artificial intelligence (AI) and diffusion tensor magnetic resonance imaging (DT-MRI) facilitates autism detection…
Read More
Excerpt from the Press Release: LONDON, Nov 16 (Reuters) – Britain has authorised a gene therapy that aims to cure sickle-cell disease and another type of inherited blood disorder for patients aged 12 and over, the country’s medical regulator said on Thursday, becoming the first in the world to do so. Casgevy is the first…
Read More
Excerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is thrilled to announce a new remarkable responder in our Phase 2 study of the…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 1, 2023 /PRNewswire/ — 280Bio, Inc., a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the first patient was treated with TEB-17231 (YL-17231), a small molecule inhibitor of RAS signaling. 280Bio is a wholly owned subsidiary of Shanghai…
Read More
NRTX-1001 investigational treatment has been well tolerated in all initial subjects Positive decision from data safety monitoring board (DSMB) on review of first cohort safety data greenlights dosing of five additional subjects in the second, highest dose, cohort First two subjects continue to report a >95% reduction in overall average monthly seizure counts one year…
Read More
Excerpt from the Press Release: Bioxodes SA has received €12 million ($13M) in a Series A funding from historic investors. This financial backing includes €8.6 million ($9.3M) in capital and €3.4 million ($3.7M) in non-dilutive funding from the Wallonia region. It comes on top of the €27 million ($29.2M) in capital and subsidies previously raised by Bioxodes, bringing to €39 million ($42.2M)…
Read More